GRI Bio to Present at the 2024 European Respiratory Congress
LA JOLLA, CA – GRI Bio, Inc. (NASDAQ: GRI) is making significant strides in the biotechnology sector with its groundbreaking methods for treating various diseases, including inflammatory, fibrotic, and autoimmune conditions. The company has announced that its abstract has been accepted for a poster presentation at the upcoming 2024 European Respiratory Congress (ERS), scheduled to take place from September 7 to 11 in Vienna, Austria.
Details of the Presentation
At this esteemed event, GRI Bio will present important research through the following poster:
- Title: Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis
- Presenter: Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London
- Poster Number: PA3381
- Session: Novel Insights in the Pathogenesis of Pulmonary Fibrosis
- Date and Time: September 9, 2024, from 12:30 - 2:00 PM CEST
Understanding GRI Bio's Focus on NKT Cells
GRI Bio is at the forefront of biopharmaceutical innovation, specifically working on Natural Killer T (NKT) cell modulators. These therapeutic strategies aim to address the underlying causes of diseases by regulating NKT cells, which are essential in the body’s inflammatory response. By concentrating on these cells, GRI Bio seeks to modify disease progression and restore the balance of the immune system.
The Role of NKT Cells in Disease
NKT cells act as a crucial link between innate and adaptive immunity. Type 1 invariant (iNKT) cells, in particular, play a vital role in controlling inflammation and fibrosis across various diseases. Modulating these cells could pave the way for innovative treatments for conditions like idiopathic pulmonary fibrosis (IPF), a serious illness that currently has no effective therapies.
GRI Bio's Pipeline and Future Endeavors
The flagship development of the company is GRI-0621, an inhibitor aimed at targeting iNKT cell activity, which is being developed as a novel oral therapy for idiopathic pulmonary fibrosis. Additionally, GRI Bio is working on type 2 NKT agonists intended for the treatment of systemic lupus erythematosus. With a rich library of over 500 proprietary compounds, GRI Bio is well-equipped to enhance its innovative therapeutic pipeline.
Investor Relations and Contact Information
For further inquiries and insights about GRI Bio, investors and interested parties can connect with the investor relations team:
Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
Frequently Asked Questions
What is GRI Bio, Inc. focused on?
GRI Bio is a biotechnology company that specializes in developing therapies aimed at Natural Killer T (NKT) cells to treat inflammatory, fibrotic, and autoimmune diseases.
Where and when will GRI Bio present its research?
GRI Bio will showcase its research at the 2024 European Respiratory Congress in Vienna, Austria, on September 9, 2024.
What is the title of GRI Bio's poster presentation?
The title of the poster presentation is 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis.'
Who is presenting the poster?
The poster will be presented by Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London.
What is GRI-0621?
GRI-0621 is GRI Bio's primary program designed to inhibit iNKT cell activity, and it is being developed as a novel oral treatment for idiopathic pulmonary fibrosis.
